Tomato recall hits US: FDA warns products sold in these 3 states may be deadly
The Food and Drug Administration (FDA) initially issued a recall on 2 May, but the situation has since escalated. On 28 May, the agency officially classified it as a Class I recall.
FDA says the affected tomatoes were sold in just three states: Georgia, North Carolina, and South Carolina. That's where the potentially contaminated produce was distributed between 23 April and 28 April under the H&C Farms Label, according to the FDA.
ALSO READ| Tomatoes recalled across 14 US states due to possible salmonella contamination
The tomatoes were packaged and shipped by Williams Farms Repack LLC, a company based in Lodge, South Carolina. While there have been no reported illnesses or deaths as of now, federal officials are urging caution.
'Freezing and drying may prevent the growth of bacteria, but do not kill salmonella,' the FDA explained. 'The bacteria can live for several weeks in dry environments and for several months in wet environments.'
5x6; R4467
6x6; R4467 and R4470
Combo, 25 pound; R4467
4x4, 2-layer; R4467
4x5, 2-layer; R4467
60-count, 2-layer; R4467
60-count, 18 pounds loose; R4467, R4470
XL, 18 pounds loose; R4467
3 count trays; R4467
'The FDA is urging anyone who bought the recalled tomatoes not to eat them and return them to the place of purchase for a full refund, or they can just discard the affected item,' the FDA said.
ALSO READ| Who is David Richardson? FEMA head under fire for saying he 'didn't know US had a hurricane season'
Centers for Disease Control and Prevention (CDC) says it's a harmful organism that can trigger diarrhea, fever, and abdominal cramps, usually within 12 to 72 hours of consumption. While most people recover without medical help, 'salmonella can cause serious and fatal infections in children, the elderly, and other people with weakened immune systems.' Pregnant women are also at risk.
'Consumers who ate the affected tomatoes and have symptoms should contact their health care provider to report their symptoms,' the FDA added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
8 hours ago
- Hindustan Times
FDA launches festive campaign to ensure food standards in the state
Mumbai: The Maharashtra Food and Drug Administration (FDA) on Monday launched a special campaign titled 'San Maharashtracha, Sankalp Anna Surakshathika Abhiyan,' to ensure hygiene and safety standards in the food sold during the upcoming festive seasons of Ganeshotsav, Eid, Navratri, Dussehra and Diwali in the state from August 11 to October 25. The campaign includes sudden inspections of eateries to keep in check food adulteration and ensure compliance with hygiene standards. The authority is also set to organise workshops to spread awareness about the standards to be met. FDA launches festive campaign to ensure food standards in the state The initiative was launched on Monday by the FDA secretary Dheeraj Kumar, along with FDA commissioner Rajesh Narvekar and senior department officials at the Yashwantrao Chavan Centre, followed by a training session for food professionals, aiming at educating traders on hygiene practices and legal compliance during the high-demand festive period. 'During festivals, the demand for sweets, modaks, faral and prasad skyrockets. This is when the risk of adulteration increases, as some traders may cut corners due to supply shortages,' FDA secretary Dheeraj Kumar said. Food businesses should strictly follow food safety standards, avoid malpractices, and ensure products are wholesome and hygienic, he added. 'We are increasing the number of food testing labs in the state. We are also working on providing manpower for the department.' FDA commissioner Rajesh Narvekar said, 'Adulteration is often detected when market demand exceeds supply. Through our training, we hope traders will comply fully with the law so that festivals can be celebrated without compromising health.' As part of the campaign, workshops on food hygiene will be conducted for those handling mandals, sweet manufacturers, and women's self-help groups that prepare festive foods. The authority will also carry out surprise inspections of food outlets, sweet shops, street vendors and production units across the state, including Mumbai, Pune, Nagpur and Chhatrapati Sambhajinagar.
Time of India
15 hours ago
- Time of India
Is Novo Nordisk facing its 'Nokia moment'? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forces
Novo Nordisk's stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal challenges fuel concerns over the Danish drugmaker's grip on the global diabetes and obesity market. Novo Nordisk, Denmark's pharma powerhouse, has seen its stock plunge from record highs as fierce competition, slowing growth, and market shifts test its dominance in the global diabetes and obesity drug market. Tired of too many ads? Remove Ads Intensifying Competitive Pressures Compounded versions from U.S. pharmacies —driven by FDA shortages—have eaten into branded sales. —driven by FDA shortages—have eaten into branded sales. Eli Lilly's Zepbound and Mounjaro are gaining prescription share. As of July 2025, Zepbound holds 59% of prescriptions compared to Wegovy's 40%, signaling a material shift in market preference. Tired of too many ads? Remove Ads Leadership Transition Amid Turbulence Legal and Regulatory Headwinds Analysts Split: Crash or Correction? Novo Nordisk: Denmark's global pharma giant Tired of too many ads? Remove Ads Key Innovative Advances Bolster Long-Term Outlook Amycretin – Dual-Action Obesity Drug: Phase 1b/2a trials show 22% average body weight loss over 36 weeks, sparking a ~12% stock bump. CagriSema – Record Weight Loss in Phase III: Achieved 20.4% weight reduction in obese adults and 13.7% in type 2 diabetes patients. Oral Semaglutide & Amycretin: Oral formulations are under U.S. regulatory review, potentially broadening adoption. $2.2B Septerna Partnership: Four programs targeting obesity, type 2 diabetes, and cardiometabolic diseases. Insulin Icodec (Awiqli) – Once-Weekly Insulin: Approved in Canada, EU, and Japan, improving patient adherence. NNC2215 – Glucose-Sensitive 'Smart' Insulin: Adjusts activity based on blood sugar, reducing hypoglycemia risk. Alhemo (Concizumab) – Hemophilia Treatment: FDA-approved July 2025 for A and B types. AI and Rare Disease Expansion: Collaborations with Heartseed, Ventus Therapeutics, and megaTAL platform targeting cardiovascular, MASH, and CKD therapies. So, Is This a 'Nokia Moment'? Summary Snapshot Indicator Status Sales & Profit Guidance Significantly lowered; investor reaction strongly negative Competition & Market Threats Rising; compounded drugs and Eli Lilly products erode share Leadership & Strategy New CEO; strategic clarity still evolving Legal & Regulatory Risks Class-action lawsuit; compounding disputes add uncertainty Valuation & Sentiment Deeply discounted; mix of caution and opportunistic value Long-term Outlook Not terminal; pipeline and global expansion offer growth levers Investor Takeaways Defensive stance: Exercise caution until guidance execution and competitive dynamics are clearer. Exercise caution until guidance execution and competitive dynamics are clearer. Value opportunity: Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Catalysts to watch: CEO performance, legal outcomes, regulatory action on compounding, and international R&D breakthroughs. FAQs: Novo Nordisk (NYSE: NVO) closed at $50.39 on Thursday, down $0.51 (-1%), extending its staggering decline from a year-high of $139.74. Investors are questioning whether the Danish pharmaceutical giant is approaching its own 'Nokia moment'—a pivotal inflection point where market dominance is challenged by nimble competitors and shifting industry Novo Nordisk lowered itsfrom. Operating profit (EBIT) growth was also trimmed to. The announcement triggered a, wiping out roughlyInvestors had expected continued dominance in the lucrative obesity and diabetes markets, but the downgrade sent an unmistakable warning: growth is slowing, and the competitive landscape is shifting Nordisk's blockbuster drugsandhave faced growing headwinds:These trends highlight a: traditional competition and unregulated compounding pharmacies undermining pricing CEOstepped down on, passing the reins to. The new CEO faces immediate challenges: stabilizing sales, defending market share, and restoring investor watchers emphasize that leadership changes at such a sensitive moment can either signal a bold strategic pivot or deepen uncertainty, depending on how quickly Doustdar asserts his Nordisk is also navigating U.S. legal scrutiny. A class-action lawsuit claims the company misled investors about competitive risks and overstated growth institutions are taking note: UBS downgraded NVO to 'neutral' and cut its target price from 600 to 340 Danish kroner, warning that competitive and compounding pressures are 'here to stay.'Market opinion is divided. Some analysts foresee additional downside, while others highlight support near $47.50 as a potential stabilization point. Contributors on Seeking Alpha argue that the sell-off may have priced in worst-case scenarios, leaving room for a measured recovery if Novo's R&D pipeline delivers next-generation weight-loss drugs or accelerates global Nordisk started its journey in Denmark in the 1920s, when two small companies—Nordisk and Novo—were founded to make insulin for people with diabetes. In 1989, the two merged to form Novo Nordisk as we know it today. The company's largest owner is the Novo Nordisk Foundation, which holds nearly a third of the shares but controls more than three-quarters of the voting in Bagsværd, just outside Copenhagen, Novo Nordisk has grown into one of the world's most valuable pharmaceutical companies. In mid-2025, it's worth around, although last year it briefly touched almost, putting it among the most valuable companies on the home, its impact is hard to overstate. Novo Nordisk is Denmark's biggest taxpayer, a major exporter, and an economic powerhouse—at one point its market value was larger than Denmark's entire GDP. Today, it's not just a national success story but a global leader in diabetes, obesity, and rare disease short-term headwinds, Novo Nordisk is pursuing multiple growth avenues:These developments suggest Novo's, providing potential long-term exactly. While Novo Nordisk faces heightened competition, slowing growth, leadership changes, and legal pressures, it retains robust cash flows, a dominant market footprint, and a promising turbulence is clear. Yet a full-scale Nokia-style collapse is unlikely given Novo's strategic assets and global reach. The company is navigating a near-term storm, but its innovation engine and expansion efforts leave the door open for Nordisk is at a critical crossroads. The company isn't collapsing, but it's clear that the weight-loss and diabetes markets are no longer uncontested territory. How the company navigates competition, regulation, and innovation in the coming months will determine whether this is a temporary stumble—or the start of a deeper stock fell after 2025 sales guidance cuts and rising competition from Eli Lilly drugs and compounded drugs and pharmacy compounding have reduced market share and investor confidence.
Economic Times
15 hours ago
- Economic Times
Is Novo Nordisk facing its 'Nokia moment'? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forces
Reuters Novo Nordisk, Denmark's pharma powerhouse, has seen its stock plunge from record highs as fierce competition, slowing growth, and market shifts test its dominance in the global diabetes and obesity drug market. Novo Nordisk (NYSE: NVO) closed at $50.39 on Thursday, down $0.51 (-1%), extending its staggering decline from a year-high of $139.74. Investors are questioning whether the Danish pharmaceutical giant is approaching its own 'Nokia moment'—a pivotal inflection point where market dominance is challenged by nimble competitors and shifting industry dynamics. On July 29, 2025, Novo Nordisk lowered its full-year 2025 sales growth forecast from 13–21% to 8–14%. Operating profit (EBIT) growth was also trimmed to 10–16% from 16–24%. The announcement triggered a 20–30% single-day stock plunge, wiping out roughly $70 billion in market capitalization. Investors had expected continued dominance in the lucrative obesity and diabetes markets, but the downgrade sent an unmistakable warning: growth is slowing, and the competitive landscape is shifting rapidly. Novo Nordisk's blockbuster drugs Wegovy and Ozempic have faced growing headwinds: Compounded versions from U.S. pharmacies —driven by FDA shortages—have eaten into branded sales. —driven by FDA shortages—have eaten into branded sales. Eli Lilly's Zepbound and Mounjaro are gaining prescription share. As of July 2025, Zepbound holds 59% of prescriptions compared to Wegovy's 40%, signaling a material shift in market preference. These trends highlight a dual threat: traditional competition and unregulated compounding pharmacies undermining pricing power. Longtime CEO Lars Fruergaard Jørgensen stepped down on August 7, 2025, passing the reins to Maziar Mike Doustdar. The new CEO faces immediate challenges: stabilizing sales, defending market share, and restoring investor confidence. Market watchers emphasize that leadership changes at such a sensitive moment can either signal a bold strategic pivot or deepen uncertainty, depending on how quickly Doustdar asserts his vision. Novo Nordisk is also navigating U.S. legal scrutiny. A class-action lawsuit claims the company misled investors about competitive risks and overstated growth prospects. Financial institutions are taking note: UBS downgraded NVO to 'neutral' and cut its target price from 600 to 340 Danish kroner, warning that competitive and compounding pressures are 'here to stay.' Market opinion is divided. Some analysts foresee additional downside, while others highlight support near $47.50 as a potential stabilization point. Contributors on Seeking Alpha argue that the sell-off may have priced in worst-case scenarios, leaving room for a measured recovery if Novo's R&D pipeline delivers next-generation weight-loss drugs or accelerates global expansion. Novo Nordisk started its journey in Denmark in the 1920s, when two small companies—Nordisk and Novo—were founded to make insulin for people with diabetes. In 1989, the two merged to form Novo Nordisk as we know it today. The company's largest owner is the Novo Nordisk Foundation, which holds nearly a third of the shares but controls more than three-quarters of the voting rights. Headquartered in Bagsværd, just outside Copenhagen, Novo Nordisk has grown into one of the world's most valuable pharmaceutical companies. In mid-2025, it's worth around $305 billion, although last year it briefly touched almost $600 billion, putting it among the most valuable companies on the planet. At home, its impact is hard to overstate. Novo Nordisk is Denmark's biggest taxpayer, a major exporter, and an economic powerhouse—at one point its market value was larger than Denmark's entire GDP. Today, it's not just a national success story but a global leader in diabetes, obesity, and rare disease treatments. Despite short-term headwinds, Novo Nordisk is pursuing multiple growth avenues: Amycretin – Dual-Action Obesity Drug: Phase 1b/2a trials show 22% average body weight loss over 36 weeks, sparking a ~12% stock bump. CagriSema – Record Weight Loss in Phase III: Achieved 20.4% weight reduction in obese adults and 13.7% in type 2 diabetes patients. Oral Semaglutide & Amycretin: Oral formulations are under U.S. regulatory review, potentially broadening adoption. $2.2B Septerna Partnership: Four programs targeting obesity, type 2 diabetes, and cardiometabolic diseases. Insulin Icodec (Awiqli) – Once-Weekly Insulin: Approved in Canada, EU, and Japan, improving patient adherence. NNC2215 – Glucose-Sensitive 'Smart' Insulin: Adjusts activity based on blood sugar, reducing hypoglycemia risk. Alhemo (Concizumab) – Hemophilia Treatment: FDA-approved July 2025 for A and B types. AI and Rare Disease Expansion: Collaborations with Heartseed, Ventus Therapeutics, and megaTAL platform targeting cardiovascular, MASH, and CKD therapies. These developments suggest Novo's core capabilities remain strong, providing potential long-term catalysts. Not exactly. While Novo Nordisk faces heightened competition, slowing growth, leadership changes, and legal pressures, it retains robust cash flows, a dominant market footprint, and a promising pipeline. Short-term turbulence is clear. Yet a full-scale Nokia-style collapse is unlikely given Novo's strategic assets and global reach. The company is navigating a near-term storm, but its innovation engine and expansion efforts leave the door open for recovery. Indicator Status Sales & Profit Guidance Significantly lowered; investor reaction strongly negative Competition & Market Threats Rising; compounded drugs and Eli Lilly products erode share Leadership & Strategy New CEO; strategic clarity still evolving Legal & Regulatory Risks Class-action lawsuit; compounding disputes add uncertainty Valuation & Sentiment Deeply discounted; mix of caution and opportunistic value Long-term Outlook Not terminal; pipeline and global expansion offer growth levers Defensive stance: Exercise caution until guidance execution and competitive dynamics are clearer. Exercise caution until guidance execution and competitive dynamics are clearer. Value opportunity: Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Catalysts to watch: CEO performance, legal outcomes, regulatory action on compounding, and international R&D breakthroughs. Novo Nordisk is at a critical crossroads. The company isn't collapsing, but it's clear that the weight-loss and diabetes markets are no longer uncontested territory. How the company navigates competition, regulation, and innovation in the coming months will determine whether this is a temporary stumble—or the start of a deeper transformation. Q1: What caused the Novo Nordisk stock plunge recently? A1: The stock fell after 2025 sales guidance cuts and rising competition from Eli Lilly drugs and compounded versions. Q2: How is Wegovy Ozempic market pressure affecting Novo Nordisk? A2: Competing drugs and pharmacy compounding have reduced market share and investor confidence.
